<DOC>
	<DOCNO>NCT01164267</DOCNO>
	<brief_summary>This multicenter open-label uncontrolled phase II study . There previous clinical data estimate expect response rate everolimus MALT lymphomas less common MZLs ( i.e . nodal splenic ) refractory relapse least 1 prior systemic treatment ( chemotherapy immunotherapy ) . The primary objective study define antitumor activity , term overall response rate ( ORR ) , sum complete remission ( CR ) partial remission ( PR ) everolimus relapse refractory marginal zone B-cell lymphoma . The secondary objective study assess safety , acute long-term toxicity , response duration ( RD ) ( time relapse progression ) responders progression-free survival ( PFS ) ( time disease progression death cause ) patient .</brief_summary>
	<brief_title>Multicenter Phase II Study Evaluate Clinical Activity Safety Profile Everolimus Marginal Zone B-cell Lymphomas ( MZL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Histologically proven diagnosis marginal zone Bcell lymphoma relapsing/refractory follow least 1 prior systemic treatment ( chemotherapy monoclonal antibody ) . 2 . Any stage ( Ann Arbor IIV ) . 3 . No evidence histologic transformation aggressive lymphoma . 4 . Measurable evaluable disease . 5 . Age &gt; 18 year . 6 . Life expectancy least 3 month . 7 . ECOG performance status 01 . 8 . No prior diagnosis neoplasm within 5 year , except cervical type 1 intraepithelial neoplasia localize nonmelanomatous skin cancer . 9 . In case prior diagnosis solid organ tumor , treatment last 5 year ond current evidence disease . 10 . No prior chemoor radiotherapy last 6 week , prior immunotherapy last 8 week , corticosteroid last 4 week unless lowdose prednisone chronically administer indication lymphoma lymphomarelated symptom . 11 . No major impairment bone marrow function , renal function liver function unless due lymphoma . 12 . No evidence active opportunistic infection , HIV infection , evidence HBV infection , active HCV infection . 13 . Women childbearing potential use effective contraception , breast feeding , pregnant agree become pregnant participation trial 12 month thereafter . A negative pregnancy test mandatory patient &lt; 50 year ( unless consider unnecessary investigator ) . Men agree father child participation trial 12 month thereafter . 14 . No serious cardiac , neurological psychiatric disorder potentially hamper compliance study protocol followup schedule . 15 . Fasting serum cholesterol ≤ 200 mg/dL ≤ 5 mmol/L AND fast triglyceride ≤ 200 mg/dL . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication . 16 . Written informed consent . 1 . Patients newly diagnose MZL . 2 . Patients concomitant past hematological malignancy . 3 . Presence history CNS lymphoma localization ( either parenchymal meningeal disease ) . 4 . Cardiovascular disease ( congestive heart failure ; NYHA III IV ) , unstable angina pectoris , significant cardiac arrhythmia require chronic treatment , prior history myocardial infarction last 3 month . 5 . Serious underlie medical condition could impair ability patient participate trial ( e.g . uncontrolled diabetes mellitus , gastric ulcer , active autoimmune disease , ongoing infection e.g . HIV , hepatitis ) . 6 . Concurrent anticancer drug / treatment experimental drug . Previous radiation allow , unless indicator lesion ( ) irradiate field . 7 . Previous organ transplantation 8 . Participation another clinical trial within 30 day prior trial entry 9 . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>